Cinclus Pharma Interim Report January June 2026
Interim report Q2 2026 - HEEALING1 Fully Enrolled – Topline Results Expected in Q4 2026
“Enrollment in our first Phase III trial, HEEALING1, is now completed as planned, and we are entering the final step before readout, expected in the fourth quarter of this year. With a robust clinical program and strong prior clinical data, we are well positioned ahead of a milestone that could define the next chapter in Cinclus Pharma’s development.”, said Christer Ahlberg, CEO of Cinclus Pharma.
Financial summary, April – June 2026
» Net sales amounted to TSEK 1,766 (34,095).
» Operating profit (EBIT) amounted to TSEK -95,031 (-45,906).
» The result for the period was TSEK -78,762 (-48,450) and earnings (loss) per share before and after dilution were SEK -1.69 (-1.04) SEK.
» Total cash flow for the period amounted to TSEK -91,353 (62,610).
» Cash and cash equivalents at the end of the period amounted to TSEK 387,916 (487,254).
Financial summary, January – June 2026
» Net sales amounted to TSEK 11,802 (34,095).
» Operating profit (EBIT) amounted to TSEK -185,885 (-93,425).
» The result for the period was TSEK -167,529 (-82,122) and earnings (loss) per share before and after dilution were SEK -3.60 (-2.22) SEK.
» Total cash flow for the period amounted to TSEK -104,065 (20,477).
» Cash and cash equivalents at the end of the period amounted to TSEK 387,916 (487,254).
Significant events during the period April – June 2026
» Cinclus Pharma announced on June 3 that the last patient had been screened in the Phase III HEEALING1 Study.
» On April 16, Cinclus Pharma’s annual report for 2025 was published, along with the notice convening the Annual General Meeting to be held on May 21, 2026.
Significant events after the end of the period
» Cinclus Pharma announced that the enrollment target for the Phase III HEEALING1 study had been achieved. A total of 521 patients were randomized as of July 2, exceeding the protocol specified target of 501 patients.
Presentation of the interim report
A webcast will be held on August 19, 2026, at 10:00 CET via Inderes. If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions.
https://cinclus-pharma.events.inderes.com/q2-report-2026
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/cinclus-pharma/q2-report-2026/dial-in